Navigation Links
Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
Date:4/3/2008

resources available, to address the myriad of reasons that contribute to nonadherence, in order to realize the full benefit of their medications."

Through On Track, Shire is providing resources and services developed with insights from experts in the nephrology and behavior modification fields to help renal care teams and patients take a multifaceted approach to hyperphosphatemia control. Shire also is offering additional support specifically for FOSRENOL patients through its comprehensive offerings in FOSRENOL On Track - a first of its kind program for the renal community that offers an array of unique services to help renal care teams and patients improve adherence.
-- Shire developed tools for HCPs and renal care teams to help enhance

their communication with patients in clinical settings. These tools

will facilitate the development of individualized plans that address

patients' specific barriers to managing their hyperphosphatemia

through diet, dialysis, and phosphate binder therapy.

-- Shire established the FOSRENOL On Track hotline to provide a simple,

single point of access to a comprehensive range of support services

and tools for all FOSRENOL patients and their renal care teams.

- FOSRENOL patients also can elect to receive regular lifestyle and

medication "reminders" through FOSRENOL On Track.

-- Knowing that high and rising out-of-pocket expenses for medications

often decrease patient adherence, Shire also is providing several

resources for FOSRENOL patients who face financial burdens to

adherence.

- Shire will provide a discount card for patients with private

insurance that will help them with financial assistance for their

medication. This is the first offering of its kind for

hyperphosphatemia patients.

- Qualified dialysis patients can receive grants t
'/>"/>

SOURCE Shire Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orqis(R) Medicals Cancion(R) System Significantly Increases Cardiac Performance
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
5. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
6. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
7. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
8. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
9. FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
10. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)...  Luminex Corporation (Nasdaq: LMNX ) today announced that ... 2013 on Monday, February 3, 2014. A press release announcing ... trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... highlights and financial results for the fourth quarter and twelve ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... WIRE via COMTEX News Network),-- Endo Pharmaceuticals ... Holdings Inc. (NASDAQ: ENDP), has presented results,from ... evaluating Frova (frovatriptan succinate) 2.5 mg,tablets as ... menstrual migraine (MM). The data demonstrated,that FROVA ...
... SALT LAKE CITY, UT, June 11, 2007 ... Genetics, Inc. (NASDAQ: MYGN) (<a target=,"_blank" href="http://www.myriad.com/">www.myriad.com ... comparison of a,"Staggered Start" and a "Randomized ... Staggered Start" clinical trial,design at the Alzheimer's ...
Cached Medicine Technology:Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 2Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 3Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 4Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 5Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 6Frova Phase III Study Data Demonstrates That Short-Term Prevention,Treatment Reduces Frequency and Severity of Menstrual Migraine 7Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 2Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 3Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 4Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification 5
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... researchers at UC Davis has shown that the cyclin ... cell division, also boosts the mitochondrial activity to power ... has been shown to perform both jobs. This newfound ... control cellular energy production, potentially advancing cancer care and ... the journal Developmental Cell . , "These proteins ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Medic, the Mecklenburg EMS,Agency, has fully ... Center, which will offer the most-advanced and,challenging ... emergency,medical services personnel. Using interactive robotic ... scene and situation, trainees face evolving,scenarios controlled ...
... that it was easy to quit smoking because he did it ... why some people find it so difficult to stop smoking even ... statistics provided by the Centers for Disease Control and Prevention (CDC), ... United States, and it is the second major cause of death ...
... features include remote printing, real-time medical necessity checking, ... for draw-station future orders., MENLO PARK, Calif., ... applications for healthcare and integration software,solutions, today announced ... Blue Iris eLaborate provides a flexible, easy-to-use, web-based ...
... Synova Healthcare Group,Inc. (OTC Bulletin Board: SNVH), today ... in aggregate notional principal amount of its,6.5% senior convertible ... common stock purchase warrants. This sale was effected as ... and warrants in the,aggregate notional principal amount of up ...
... NEW YORK Repeated courses of a drug that ... babies also may increase the risk of cerebral palsy ... study, funded by the National Institutes of Health and ... gynecology, Columbia University Medical Center and attending obstetrician and ...
... to female sex-change surgery are happy with the results, despite ... of over 200 patients in the September issue of the ... the Departments of Urology and Psychiatry at University Hospitals of ... patients who had undergone surgery and 70 who took part ...
Cached Medicine News:Health News:Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel 2Health News:Genetic variation affects smoking cessation treatment 2Health News:MITEM Releases Blue Iris eLaborate 8.6 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 2Health News:Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants 3Health News:Repeat steroids to premature infants linked to cerebral palsy 2Health News:Most patients who have male-to-female sex-change surgery are happy, despite complications 2
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Medicine Products: